These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 25935787

  • 1. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC, Brown MM, Turpcu A, Rajput Y.
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [Abstract] [Full Text] [Related]

  • 2. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 3. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Monigle MC.
    Ophthalmol Retina; 2024 May; 8(5):431-446. PubMed ID: 37981235
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS, Lane SS.
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
    Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW.
    Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
    [Abstract] [Full Text] [Related]

  • 6. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 7. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
    Bressler NM, Varma R, Suñer IJ, Dolan CM, Ward J, Ehrlich JS, Colman S, Turpcu A, RIDE and RISE Research Groups.
    Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
    Ip MS, Domalpally A, Sun JK, Ehrlich JS.
    Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
    Haig J, Barbeau M, Ferreira A.
    J Med Econ; 2016 Jul; 19(7):663-71. PubMed ID: 26882365
    [Abstract] [Full Text] [Related]

  • 14. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Hutton DW, Stein JD, Glassman AR, Bressler NM, Jampol LM, Sun JK, DRCR Retina Network.
    JAMA Ophthalmol; 2019 Dec 01; 137(12):1424-1432. PubMed ID: 31647496
    [Abstract] [Full Text] [Related]

  • 15. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
    Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, RISE and RIDE Research Group.
    Ophthalmology; 2012 Apr 01; 119(4):789-801. PubMed ID: 22330964
    [Abstract] [Full Text] [Related]

  • 16. Clinical applications of cost analysis of diabetic macular edema treatments.
    Smiddy WE.
    Ophthalmology; 2012 Dec 01; 119(12):2558-62. PubMed ID: 23062655
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.
    Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K, Knudsen M, Onwordi H.
    Br J Ophthalmol; 2012 May 01; 96(5):688-93. PubMed ID: 22399690
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ, RIDE and RISE Research Group.
    Ophthalmology; 2013 Oct 01; 120(10):2013-22. PubMed ID: 23706949
    [Abstract] [Full Text] [Related]

  • 19. Cataract surgery cost utility revisited in 2012: a new economic paradigm.
    Brown GC, Brown MM, Menezes A, Busbee BG, Lieske HB, Lieske PA.
    Ophthalmology; 2013 Dec 01; 120(12):2367-2376. PubMed ID: 24246824
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.